JP Morgan Chase
CODX

JP Morgan Chase’s Co-Diagnostics CODX Stock Holding History

JP Morgan Chase’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,080
Closed -$869K – 5663
2020
Q3 		$869K Buy
+2,080
New +$1.07M ﹤0.01% 3719

Other funds holding CODX

PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $2.77B AUM 22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

JP Morgan Chase's CODX Position: Q1 2026 in Review

JP Morgan Chase increased its Co-Diagnostics (CODX) stake by 127% in Q1 2026, buying an estimated $96 and bringing the position to 50 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #7322.

JP Morgan Chase first reported a position in CODX in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.19M in Q3 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • JP Morgan Chase held 50 shares of Co-Diagnostics worth $85 as of Q1 2026.
  • JP Morgan Chase bought 28 Co-Diagnostics shares in Q1 2026, an estimated $96.
  • Co-Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7322 holding.
  • JP Morgan Chase first reported a position in Co-Diagnostics in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Co-Diagnostics position peaked at $1.19M in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.